Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.11.008Source: DataRank Database

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation is a research paper published in Journal of Cystic Fibrosis (2020). On theSindex it has a DataRank of 0. It has been cited 64 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access64 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)OA: bronzeTopics (47)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Arthur Baines ORCID,Alex Paynter ORCID,Sonya L. Heltshe ORCID,Jill M. VanDalfsen,Manu Jain ORCID

Live enrichment

PubMed:33249004 PMC:PMC8183611

NCATS NIH HHS

Grant: UL1 TR002535

NHLBI NIH HHS

Grant: R35 HL135816

NIDDK NIH HHS

Grant: P30 DK089507

NCATS NIH HHS

Grant: UL1 TR003096

NHLBI NIH HHS

Grant: K23 HL143167

NIDDK NIH HHS

Grant: P30 DK072482

National Institutes of Health

Grant: 3UL1TR002535-03S1

NIH Prior Approval Process Professional

National Institutes of Health

Grant: 5R35HL135816-04

Translational Program in CFTR-Related Airway Diseases

National Institutes of Health

Grant: 7K23HL143167-05

Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients

National Institutes of Health

Grant: 3P30DK072482-03S3

UAB CF Research and Translation Core Center

National Institutes of Health

Grant: 3UL1TR003096-02S3

Center for Clinical and Translational Science

National Institutes of Health

Cystic Fibrosis Foundation Therapeutics

bronzeLicense: Elsevier Non-Commercial

publisherhttps://www.cysticfibrosisjournal.com/article/S1569-1993(20)30911-5/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1569199320309115?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199320309115?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8183611

https://doi.org/10.1016/j.jcf.2020.11.008

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansPseudomonas aeruginosaPseudomonas InfectionsCystic FibrosisAminophenolsQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorRespiratory Function TestsLongitudinal StudiesProspective StudiesGenotypeMutationQuality of LifeAdolescentAdultChildUnited StatesFemaleMaleMutant ProteinsChloride Channel Agonists

Keywords

Pseudomonas aeruginosaQuality of lifeLung functionCftrIvacaftorSweat ChlorideAdultMaleAdolescentCystic FibrosisGenotypeCystic Fibrosis Transmembrane Conductance RegulatorQuinolonesAminophenolsRespiratory Function TestsMutationHumansFemaleMutant ProteinsPseudomonas InfectionsLongitudinal StudiesProspective StudiesChildChloride Channel Agonists

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

10.6084/m9.figshare.26713634.v1figshare

Additional file 1 of Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

10.6084/m9.figshare.26713634figshare